Golden Meditech Announces the Disposal of Convertible Note Issued by CCBC for over US$88 million

HONG KONG, Aug. 25, 2014 /PRNewswire/ -- Golden Meditech Holdings Limited (the "Company" or "Golden Meditech", 801.HK; 910801.TW), a leading integrated healthcare enterprise in China, announced that it has entered into an agreement to sell its 7% senior convertible note due 2017 in an aggregate principal amount of US$50 million issued on 3 October 2012 by China Cord Blood Corporation ("CCBC"), a non-wholly-owned subsidiary of the Company ("Convertible Note") to Magnum Opus International Holdings Limited ("Magnum") and Cordlife Group Limited ("CGL") for approximately US$88,090,000 (equivalent to approximately HK$682,697,500) in cash (the "Disposal"). Upon completion of the Disposal, each of Magnum and CGL will hold 50% of the Convertible Note.

Magnum is a private vehicle controlled by Mr. Kam Yuen, Chairman and Chief Executive Officer of the Company and Chairman of CCBC, and involves the CCBC management team. CGL is a cord blood banking services operator listed on the main board of the Singapore Exchange Securities Trading Limited, which currently owns approximately 10% of the issued shares of CCBC.

Following completion of the Disposal, Golden Meditech's shareholding in CCBC will remain unchanged at approximately 42.0% and will only be diluted to approximately 33.9% if both Magnum and CGL exercise their rights to convert their Convertible Note into CCBC shares and, accordingly, their respective shareholdings in CCBC would increase by approximately 9.7%.

With mainland China's healthcare sector continues to be driven by the government's healthcare reform, Golden Meditech believes the Disposal would strengthen its financial position and liquidity, enhancing its ability to fund its potential acquisitions or expansion of its existing healthcare related businesses in mainland China.

The transaction is subject to Golden Meditech and CGL obtaining all relevant approvals and consents, including but not limited to the approval of Golden Meditech's independent shareholders. An Extraordinary General Meeting ("EGM") will be convened to consider and approve the transaction and a circular containing details of the Disposal and a notice of EGM are expected be dispatched to the shareholders no later than 16 September 2014.

About Golden Meditech Holdings Limited

Golden Meditech Holdings Limited (www.goldenmeditech.com) is China's leading integrated-healthcare enterprise. Golden Meditech is a first-mover in China, having established dominant positions in medical devices and healthcare services markets, including cord blood stem cells storage and hospital management, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, the Group will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.

SOURCE Golden Meditech Holdings Limited